Lista de obras - Philippe Rousselot - Dominio Público Uruguay

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

artículo científico publicado en 2014

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

artículo científico publicado en 2003

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

artículo científico publicado en 2016

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

artículo científico publicado en 2016

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

artículo científico publicado en 2006

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

artículo científico publicado en 2016

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

artículo científico

Discovery of five irregular moons of Neptune

artículo científico publicado en 2004

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

artículo científico publicado en 2012

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

artículo científico publicado en 2013

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

artículo científico publicado en 2005

Frequent antibody production against RARalpha in both APL mice and patients

artículo científico publicado en 2006

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

artículo científico publicado en 2006

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

artículo científico publicado en 2015

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

artículo científico publicado en 2010

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

artículo científico publicado en 2014

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

artículo científico publicado en 2014

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

artículo científico publicado en 2011

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

artículo científico publicado en 2015

OSSOS. IV. Discovery of a dwarf planet candidate in the 9:2 resonance with Neptune ⬇️

artículo científico publicado en 2016

OSSOS. VII. 800+ Trans-Neptunian Objects—The Complete Data Release

artículo científico publicado en 2018

OSSOS. XI. No active centaurs in the Outer Solar System Origins Survey

artículo científico publicado en 2019

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

artículo científico publicado en 2011

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

artículo científico publicado en 2010

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

artículo científico publicado en 2013

Pulmonary Complications of Bcr-Abl Tyrosine Kinase Inhibitors

artículo científico publicado en 2020

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

artículo científico publicado en 2018

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

artículo científico publicado en 2010

The outer solar system origins survey. I. Design and first-quarter discoveries ⬇️

artículo científico publicado en 2016

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

artículo científico publicado en 2009

Lista de obras de Philippe Rousselot

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Discovery of five irregular moons of Neptune

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells.

Frequent antibody production against RARalpha in both APL mice and patients

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

OSSOS. IV. Discovery of a dwarf planet candidate in the 9:2 resonance with Neptune ⬇️

OSSOS. VII. 800+ Trans-Neptunian Objects—The Complete Data Release

OSSOS. XI. No active centaurs in the Outer Solar System Origins Survey

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

Pulmonary Complications of Bcr-Abl Tyrosine Kinase Inhibitors

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

The outer solar system origins survey. I. Design and first-quarter discoveries ⬇️

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).